BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Semaglutide
1
Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis
3/23/2026 8:54:21 AM | Browse: 19 | Download: 80
2
Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy
2/6/2026 8:43:33 AM | Browse: 49 | Download: 185
3
Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease
12/23/2025 8:03:21 AM | Browse: 72 | Download: 172
4
Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice
10/27/2025 10:57:49 AM | Browse: 159 | Download: 375
5
Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation
7/22/2025 8:44:58 AM | Browse: 83 | Download: 555
6
Finerenone and semaglutide: Role in heart failure with reduced ejection fraction
5/23/2025 9:07:55 AM | Browse: 166 | Download: 439
7
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
11/29/2024 8:40:08 AM | Browse: 131 | Download: 510
8
Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction–associated steatotic liver disease
8/9/2024 12:51:13 PM | Browse: 250 | Download: 761
9
Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications
7/11/2024 8:47:17 AM | Browse: 218 | Download: 635
10
Semaglutide for the management of diabesity: The real-world experience
6/25/2024 9:25:52 AM | Browse: 257 | Download: 976
11
Impact of glucagon-like peptide receptor agonists on endoscopy and its preoperative management: Guidelines, challenges, and future directions
6/14/2024 9:22:25 AM | Browse: 119 | Download: 588
12
Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon
2/4/2024 10:57:41 AM | Browse: 304 | Download: 911
13
Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1
12/27/2023 5:42:53 AM | Browse: 338 | Download: 1310
14
Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis
12/19/2023 2:09:20 AM | Browse: 527 | Download: 1195
15
Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
9/25/2023 9:07:43 AM | Browse: 423 | Download: 1386
16
Semaglutide-eye-catching results
4/12/2023 11:34:59 AM | Browse: 363 | Download: 1053
17
Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
7/5/2022 1:22:29 AM | Browse: 553 | Download: 1313
18
Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
9/11/2020 7:11:20 AM | Browse: 811 | Download: 1649
19
Effects of glycaemic management on diabetic kidney disease
5/15/2017 10:13:33 AM | Browse: 1672 | Download: 2072
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345